VCYT Q4 2020 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$35M+16.2% YoY

Gross Profit

$23M67.6% margin

Operating Income

-$8M-23.4% margin

Net Income

-$8M-23.3% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+11.0%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$1M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$457M

Total Liabilities

$36M

Stockholders' Equity

$421M

Cash & Equivalents

$349M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$30M	+16.2%
Gross Profit	$23M	$20M	+19.1%
Operating Income	-$8M	-$8M	+1.5%
Net Income	-$8M	-$7M	-7.9%

Revenue Segments

Testing

$31M91%

Product

$3M8%

Biopharmaceutical

$343,0001%